GlobalData found that Oncology was the largest therapy area for clinical trials in...
Getting Acquainted with the Theory of XRF
This white paper provides a general introduction to X-ray Fluorescence (CRF) spectrometry and XRF analysis. It explains how a spectrometer works and how XRF analysis is achieved.
Adcetris® for the Treatment of Relapsed or Refractory Hodgkin’s Lymphoma
Adcetris® (brentuximab vedotin) is a treatment for relapsed or refractory (r/r) Hodgkin’s lymphoma (HL) and anaplastic large cell lymphoma (ALCL) that was developed by Seattle Genetics and Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceutical.
Detecting the Presence of Trace Polymorphs and Impurities
In the pharmaceutical industry, the detection of polymorph traces is one of the most important applications of powder x-ray diffraction (PXRD).
Blincyto® (blinatumomab) for the Treatment of B-cell Precursor Acute Lymphoblastic Leukaemia
Blincyto® (blinatumomab) is a monoclonal antibody indicated as a treatment for relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL) in adults and children.
Tradjenta Indicated for the Treatment of Type II Diabetes
Linagliptin (BI-1356), which is being marketed under the trade name Tradjenta®, is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor drug for the treatment of type 2 diabetes.
Dupixent (dupilumab) for the Treatment of Atopic Dermatitis
Dupixent (dupilumab) is an investigational drug being developed by Sanofi and Regeneron as a treatment for moderate to severe atopic dermatitis in adult patients.
Large Range of High-Quality Primary Cells and Reagents
Caltag Medsystems strives to be a one stop shop for all your cell culture needs. To meet the demands of its clients, the company’s primary cell portfolio is constantly growing and it has an extensive range from multiple partners, including Sciencell, AllCells, Neuromics and C&M Lab Pro.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.